Trogarzo FDA Approval History
FDA Approved: Yes (First approved March 6, 2018)
Brand name: Trogarzo
Generic name: ibalizumab-uiyk
Dosage form: Injection
Company: TaiMed Biologics USA Corp.
Treatment for: HIV Infection
Trogarzo (ibalizumab-uiyk) is a CD4-directed post-attachment HIV-1 inhibitor for the treatment of multidrug resistant human immunodeficiency virus-1 (HIV-1) infection in heavily treatment-experienced adults.
Development Timeline for Trogarzo
|Mar 6, 2018||Approval FDA Approves Trogarzo (ibalizumab-uiyk) for Treatment-Experienced Patients with Multidrug Resistant HIV|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.